Press Releases April 30, 2026 09:00 AM

WidePoint Sets First Quarter 2026 Conference Call for Thursday, May 14, 2026, at 4:30 p.m. ET

WidePoint Announces Q1 2026 Earnings Conference Call for May 14, 2026

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
WYY

WidePoint Corporation will hold its first quarter 2026 earnings conference call on May 14, 2026, to discuss financial results for the quarter ended March 31, 2026. The company will release its financial results prior to the call and provide a live broadcast with an opportunity for investor Q&A.

WidePoint Sets First Quarter 2026 Conference Call for Thursday, May 14, 2026, at 4:30 p.m. ET
WYY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • WidePoint is scheduled to report Q1 2026 financial results and host a conference call with management on May 14, 2026.
  • The company focuses on secure mobile management solutions including IAM, MMS, Telecom Management, Cloud Security, and related services.
  • WidePoint operates as a technology managed solution provider dedicated to securing mobile workforce and enterprise environments.
  • Impacted sectors include technology, cybersecurity, telecommunications, and enterprise IT services.

FAIRFAX, Va., April 30, 2026 (GLOBE NEWSWIRE) -- WidePoint Corporation (NYSE American: WYY), a leading provider of Secure Mobile Management Solutions, will hold a conference call on Thursday, May 14, 2026, at 4:30 p.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2026. Financial results will be issued in a press release prior to the call.

WidePoint’s management will host the conference call, followed by a question and answer period.

Date: Thursday, May 14, 2026
Time: 4:30 p.m. ET (1:30 p.m. PT)
U.S. dial-in number: 888-506-0062
International number: 973-528-0011
Access Code: 321002

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Group at (949) 574-3860.  

The conference call will be broadcast live and available for replay here and via the investor relations section of the company’s website. A replay of the conference call will be available after 7:30 p.m. ET on the same day through Thursday, May 28, 2026.

Toll-free replay number: 877-481-4010
International replay number: 919-882-2331
Replay ID: 53882

About WidePoint
WidePoint Corporation (NYSE American: WYY) is a leading technology Managed Solution Provider (MSP) dedicated to securing and protecting the mobile workforce and enterprise landscape. WidePoint is recognized for pioneering technology solutions that include Identity & Access Management (IAM), Mobility Managed Services (MMS), Telecom Management, Information Technology as a Service, Cloud Security, and Analytics & Billing as a Service (ABaaS). To learn more, visit https://www.widepoint.com. 

WidePoint Investor Relations:
Gateway Group, Inc.
Matt Glover or John Yi
949-574-3860
WYY@gateway-grp.com


Risks

  • The actual financial results could deviate from investor expectations, potentially impacting stock performance.
  • Market volatility or external economic conditions affecting the tech and cybersecurity sectors could influence WidePoint's outlook.
  • Uncertainties around the adoption rate and competitive landscape in secure mobile management services may affect future growth prospects.

More from Press Releases

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026